Elanco Animal Health (XTER:5EA) Stock Based Compensation: €64 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:5EA Elanco Animal Health Inc XTER:5EA
74 GF Score
Price €20.06
GF Value €14.97
! 2 Warning Signs
View Full Analysis

What is Elanco Animal Health Stock Based Compensation?

Elanco Animal Health XTER:5EA 74 Stock Based Compensation is €64 Mil as of Jun. 2026. GuruFocus rates XTER:5EA with a GF Score™ of 74/100 and a GF Value™ of €14.97. The stock has 2 warning signs investors should review.

Elanco Animal Health's Stock Based Compensation for the three months ended in Jun. 2026 was €17 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was €64 Mil.

Elanco Animal Health Stock Based Compensation Related Terms

Elanco Animal Health Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Elanco Animal Health's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elanco Animal Health Stock Based Compensation Chart

Elanco Animal Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 58.41 55.70 42.18 52.53 58.07

Elanco Animal Health Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.34 14.48 13.66 18.17 17.36
XTER:5EA
74GF Score
Elanco Animal Health Inc XTER:5EA
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elanco Animal Health Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €64 Mil.

What does a Stock Based Compensation of €64 Mil mean?
Elanco Animal Health (XTER:5EA) has a Stock Based Compensation of €64 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Elanco Animal Health and its competitors.
Is Elanco Animal Health's Stock Based Compensation too high?
Elanco Animal Health's current Stock Based Compensation is €64 Mil. Overall, Elanco Animal Health has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Elanco Animal Health's Stock Based Compensation compare to ALKS and LQDA?
Elanco Animal Health's Stock Based Compensation of €64 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Elanco Animal Health and its competitors. Elanco Animal Health's current Stock Based Compensation is €64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elanco Animal Health stock overvalued right now?
Elanco Animal Health (XTER:5EA) has a current Stock Based Compensation of €64 Mil. The stock's GF Value™ is €14.97, compared to a current price of €20.06 — trading 34% above its estimated fair value. The current Stock Based Compensation is €64 Mil. Elanco Animal Health's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Elanco Animal Health (XTER:5EA), the current Stock Based Compensation is €64 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Elanco Animal Health (XTER:5EA) Overvalued in 2026?

Based on GuruFocus' analysis, Elanco Animal Health stock appears to be overvalued. The current stock price of €20.06 is trading 34% above its estimated GF Value™ of €14.97.

Key valuation signals for XTER:5EA:

  • Stock Based Compensation: €64 Mil
  • GF Value™: €14.97 vs. price of €20.06 (34% above fair value)
  • GF Score™: 74/100 with 2 warning signs

No single metric tells the full story. See the XTER:5EA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Elanco Animal Health Business Description

Other Exchanges ELAN:USA5EA:Germany
Address 450 ELANCO CIRCLE, INDIANAPOLIS, IN, USA, 46221
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
74GF Score

Get the complete analysis for XTER:5EA

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.06
Price
€14.97
GF Value